Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"),...
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies...
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated...
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced...
MARCY-L'ÉTOILE, France, April 9, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the...
– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider...
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The...
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present...
CHICAGO, IL / ACCESS Newswire / April 6, 2026 / On April 15, ACOFP, in collaboration with sponsors Sanofi and...
AIAW26 Runs April 6-10, Highlights the Critical Role of Well-Visits and AAP-Recommended ImmunizationsVENTNOR CITY, N.J., April 02, 2026 (GLOBE NEWSWIRE)...
SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a...
Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancerPHILADELPHIA, April 01, 2026...
Next-generation life sciences executive search firm supports venture-backed antibody discovery company in securing life-changing scientific leadershipHERNDON, Va., March 31, 2026...
4basebio PLC ("4basebio" or the "Company") Cambridge, UK, 31 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic...
Expanding nucleic acid delivery business with new applicationsOngoing optimization of cost structureAdvancing plans for spin-off of nucleic acid delivery business...
TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney...
SOUTH SAN FRANCISCO, Calif., March 30, 2026 /PRNewswire/ -- Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for...